HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Physician, patient education needed to increase lung cancer screening rate
• Should a model-based approach be used to identify which individuals should undergo lung cancer screening?
• The cost of success: After the cure of testis cancer Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Preventing meningococcal disease in patients receiving Soliris Leah Molloy, PharmD
• Clinical presentation suggests spinal neoplasm, but is it really a tumor? Munir Ghesani, MD, FACNM; Juhi M. Purswani; Ana M. Franceschi, MD
• Training, retaining APPs ‘of paramount importance’ to oncology workforce Mark Hyde, PhD, PA-C
• Researchers: Off-label cancer treatment recommendations often based on weak evidence
• Gene editing may enhance CAR T-cell therapy for hematologic malignancies
• Small molecule inhibitor appears effective, safe for advanced head and neck cancer
• Cheek swab may help diagnose precancers, early malignancies
• Use of conservative management for low-risk prostate cancer ‘increasing rapidly’
• MD Anderson Cancer Center’s colorectal cancer moon shot team designed to make fundamental changes in detection, treatment
• Topical gel may help decrease breast density
• Avelumab yields durable response at 18 months for advanced Merkel cell carcinoma
• Ibrutinib plus rituximab improves PFS in Waldenström’s macroglobulinemia
• Radioactive iodine does not have significant benefit for recurrent thyroid cancer
• L-glutamine reduces painful crises associated with sickle cell disease
• Lymphocyte infusion, second stem cell transplant offer comparable OS for relapsed acute myeloid leukemia
• Pomalidomide, low-dose dexamethasone active in multiple myeloma with renal impairment
• Tanning bed users more likely to examine skin for cancer
• Liquid biopsy predictive of survival for metastatic triple-negative breast cancer
• Researchers identify factors associated with survival in diffuse intrinsic pontine glioma
• Dasatinib safe, effective for pediatric chronic myeloid leukemia in chronic phase
• Diet soft drinks linked to reduced colon cancer recurrence, mortality
• Immunochemotherapy remains standard induction for follicular lymphoma
• Minimally invasive surgery effective for early-stage lung cancer
• Brain metastases common during treatment with crizotinib for ROS1-positive NSCLC
• STAG2 identified as biomarker for bladder cancer recurrence, progression
• Morbidity burden identifies testicular cancer survivors who need close monitoring
• Late-onset diabetes may be early sign of pancreatic cancer among African-Americans, Latinos
• BRAF V600E mutations linked to worse survival in metastatic colorectal cancer
• Treatment-related amenorrhea incidence consistent among anti-HER-2 regimens
• New recommendations reflect ‘continued evolution’ of cervical cancer screening
• FDA approves cobas EGFR Mutation Test for use with Iressa in lung cancer
• FDA grants fast track designation to AVB-S6-500 for ovarian cancer
• FDA grants orphan drug designation to ASLAN003 for acute myeloid leukemia
• FDA grants regular approval to Keytruda-chemotherapy combination for nonsquamous non-small cell lung cancer
• FDA grants priority review to Empliciti combination for multiple myeloma
• FDA updates prescribing information for Keytruda, Tecentriq
• FDA approves Lenvima for unresectable hepatocellular carcinoma
• FDA grants priority review to Elzonris for blastic plasmacytoid dendritic cell neoplasm
• FDA approves Opdivo for metastatic small cell lung cancer
• FDA approves Onpattro, first treatment for polyneuropathy caused by rare genetic disease
• CMS panel expresses confidence in patient-reported outcomes tools
• UK panel rejects CAR T-cell therapy due to cost
• ASH to honor several leaders in hematology
• Association of American Cancer Institutes names president-elect
• Cancer Treatment Centers of America announces two promotions
• Alpelisib improves PFS for advanced PIK3CA-mutated breast cancer